This will support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market.

Anne Wojcicki, co-founder and former CEO of 23andMe, is set to regain control of the DNA-testing company after a nonprofit ...

Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

Ecolab has launched a new resin designed to help achieve cost savings and optimize operations throughout the antibody ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...

BioNTech has agreed to acquire CureVac, a clinical-stage biotech company developing a novel class of transformative medicines ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

The research program will combine Debiopharm’s AbYlink conjugation technology with Alkyon’s modular antibody platform and ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

PL BioScience GmbH, a German life science company, has appointed Oliver Dick, PhD, as Chief Technology Officer.

The collaboration aims to advance the discovery and development of novel oral candidates.